Investors weighing Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ) face a familiar healthcare trade-off: a focused biopharma offering a low valuation and high dividend yield, or a diversified medical giant delivering stronger profitability and steadier growth at a premium.
BMY focuses on high-impact areas such as oncology, hematology and cardiovascular health. Products are distributed mainly through wholesalers and specialty pharmacies, with expanding direct-to-patient channels. In fiscal 2025, revenue reached nearly $48.2 billion, down about 0.2% year over year. Net income was roughly $7.1 billion, a significant turnaround from the prior-year net loss, producing a net margin of about 14.6%.
Valuation is the bull case. BMY trades at about 9.1x forward earnings, 2.7x sales and 13.47x trailing earnings. Its dividend is $2.51 per share, a yield of about 4.10%, making it the more value-oriented and income-focused option. But the balance sheet carries more leverage. Debt-to-equity is about 2.6x, above some peers. The current ratio is about 1.3x, and free cash flow was nearly $12.8 billion, still enough to fund research and development.
Risks include government-mandated price controls under the Inflation Reduction Act, particularly for Eliquis; patent expirations that could invite generic competition and revenue declines; a revived $6.7 billion lawsuit tied to the Celgene acquisition; and ongoing patent disputes with Cytokinetics.
JNJ operates through innovative medicine and medtech, serving global markets with immunology and neuroscience treatments as well as surgical and orthopedic tools. The company plans to separate its orthopedics business within the next 18 to 24 months. In fiscal 2025, revenue was about $94.2 billion, up nearly 6% year over year. Net income was roughly $26.8 billion, for a net margin of about 28.5%. That reflects stronger profitability and steady demand across its diversified portfolio.
Its financial position is more conservative. Debt-to-equity is about 0.6x, the current ratio is near 1.0x, and free cash flow was about $19.7 billion, giving it ample capital for dividends and internal investment. The trade-off is valuation. JNJ trades at about 23.4x forward earnings, 6.9x sales and 31.20x trailing earnings. Its dividend is $5.28 per share, a yield of about 1.96%, roughly half of BMY’s.
JNJ also faces risks: pricing pressure on products such as Stelara and Xarelto; long-running mass tort claims related to talc-based body powders; execution risk around the orthopedics separation; and competition from large pharmaceutical peers including Merck and Pfizer.
If the priority is low valuation and high dividend income, BMY screens as the more attractive choice—provided investors can tolerate patent cliffs, litigation and higher leverage. If the priority is high profitability, steady growth, lower debt and stronger cash flow, JNJ stands out, even though it commands a premium valuation and offers a lower yield. The decision ultimately depends on whether investors favor value and income or quality and growth.
